LandBridge
LB
70.39
-1.04
-1.46%
LandBridge
US · LB
#1859 by market cap
Listed 2024
70.39
-1.04
-1.46%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
Piper Sandler Maintains LandBridge(LB.US) With Hold Rating, Maintains Target Price $88Market Newswire · 2026/10/12
-
Piper Sandler Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/11/6
-
Rating change
LB Pharmaceuticals, Inc. (LBRX) Gets a Buy From GuggenheimTipRanks · 2026/10/13
-
Company notice
Lb Semicon: Report on Status of Specific Securities, Etc. Owned by Executives and Major ShareholdersOPENDART · 2026/8/19
-
Rating change
Raymond James Maintains LandBridge(LB.US) With Buy Rating, Raises Target Price to $91Market Newswire · 2026/10/19
-
BMO Capital Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $54Market Newswire · 2026/11/6
-
Rating change
CCORF Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $65Market Newswire · 2026/10/9
-
Rating change
Barclays Maintains LandBridge(LB.US) With Hold Rating, Maintains Target Price $75Market Newswire · 2026/11/6
-
Guggenheim Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $80Market Newswire · 2026/11/13
-
Company notice
Nippecraft: Financial Statements and Related Announcement-Notification of Results ReleaseSGX · 2026/7/9
-
H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/11/9
-
Company notice
Nippecraft: Financial Statements and Related Announcement-Half Yearly ResultsSGX · 2026/8/12
-
Company notice
4: LB Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Deep Track Biotechnology Master Fund, Ltd.SEC · 2026/8/4
-
Company notice
Lb Semicon: Report on Significant Holdings of Stocks, Etc. (General)OPENDART · 2026/9/29
-
Rating change
A Quick Look at Today's Ratings for LB Pharmaceuticals(LBRX.US), With a Forecast Between $54 to $80Market Newswire · 2026/10/28
-
Rating change
Goldman Sachs Maintains LandBridge(LB.US) With Buy Rating, Raises Target Price to $97Market Newswire · 2026/10/12
-
Rating change
Analysts Offer Insights on NA Companies: SpaceX (SPCX), Six Flags Entertainment Corporation (FUN) and LB Pharmaceuticals, Inc. (LBRX)TipRanks · 2026/10/21
-
Rating change
Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $53Market Newswire · 2026/10/21
-
Rating change
LB Pharmaceuticals, Inc. (LBRX) Gets a Buy From H.C. WainwrightTipRanks · 2026/10/12
-
CCORF Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/11/7
-
Rating change
Piper Sandler Maintains LandBridge(LB.US) With Hold Rating, Raises Target Price to $88Market Newswire · 2026/9/1
-
Rating change
Guggenheim Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $80Market Newswire · 2026/10/13
-
Rating change
Needham Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $68Market Newswire · 2026/10/2
-
Piper Sandler Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/10/29
-
Rating change
Citi Initiates LandBridge(LB.US) With Hold Rating, Announces Target Price $86Market Newswire · 2026/8/26
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.
LandBridge discussion 0 comments